Back to search results

Phase 1 Study of JMT108 for Advanced Solid Tumors

This study is testing a new drug called JMT108 in adults with advanced solid tumors (cancers that form solid masses) that have not responded to standard treatments or for which no standard treatment exists. JMT108 is a type of immunotherapy and targeted therapy called a bispecific antibody. The main goals are to find a safe dose of JMT108, see how well it works against tumors, and understand how your body processes it. To join, you must be at least 18 years old, have advanced solid tumors, and have at least one measurable tumor. The study is currently recruiting up to 270 participants.

Study design
This is a Phase 1 study with two parts: a dose-escalation phase to find the right dose and an expansion phase. It is a single-arm study, meaning all participants receive JMT108, and plans to enroll up to 270 participants.
What's involved
Participants will undergo a screening period, receive JMT108 by intravenous injection during a treatment period, have an end-of-treatment visit, and enter a follow-up period.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for safety and tumor response through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07317505

A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
Conjupro Biotherapeutics, Inc.
~270 participants
Updated 2026-01-21 on ClinicalTrials.gov
What's tested:JMT108

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with Dose Limiting Toxicities as assessed by NCI CTCAE v5.0 (excluding cytokine release syndrome, CRS).
Measured over through study completion, an average of 1 year
+1 more outcome measured

Conditions

Cancer
Cancer (Solid Tumors)

Explore related trials

Colorectal CarcinomaGastric CarcinomaMalignant Liver NeoplasmMelanomaSolid Neoplasm

Where it's being run

3 sites across 3 states
North Carolina1
Texas1
Virginia1

Who to contact

Kevin Romanko
[email protected]
609-686-6502
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years
Participants with histologically or cytologically confirmed locally advanced or metastatic solid tumors who are unresponsive or intolerant to all standard of care or have no standard of care available
At least one evaluable tumor lesion according to RECIST v1.1.
ECOG performance status score ≤2.
Expected survival ≥ 3 months

Exclusion

Active central nervous system metastases and/or leptomeningeal metastases
AEs from prior therapy which have not recovered to Grade ≤1 or baseline as per NCI CTCAE v5.0
Any other unapproved investigational drugs or treatments within 4 weeks prior to the first dose of the investigational drug (C1D1).
Chemotherapy, radiotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy, or other anti-tumor therapies within 4 weeks prior to the first dose of the investigational drug, except in the following situations:

What this trial measures

  • Number of participants with Dose Limiting Toxicities as assessed by NCI CTCAE v5.0 (excluding cytokine release syndrome, CRS).through study completion, an average of 1 year

    To evaluate the safety and tolerability of JMT108 to determine the dose and schedule to be used in phase 1b.

  • Number of participants with Tumor Response as assessed by RECIST version 1.1 criteriathrough study completion, an average of 1 year

    To evaluate preliminary efficacy of JMT108 injection as monotherapy in participants with advanced malignant tumors.